Half of the roughly 30 dogs at the nonprofit shelter SpokAnimal have contracted a yet-to-be-identified respiratory illness that’s led to some cases of pneumonia and the temporary closure of the ...

Please provide your email address to receive an email when new articles are posted on . The ICoN-1 trial has been discontinued, and futility was the reason for this decision. The company is still ...

(StatePoint) If you’re one of the 35 million people living with a chronic lung disease in the United States, the form of treatment you receive can impact your health outcomes and quality of life. That ...

Good morning, and welcome to MannKind Corporation's investor call to discuss a clinical trial update. As a reminder, this call is being recorded on November 10, 2025, and will be available for ...

Background: Long-acting beta-agonist (LABA) plus long-acting muscarinic antagonist (LAMA) is superior to monotherapy or corticosteroid/LABA in terms of improving lung function, alleviating symptoms ...

Can you eat your way to keeping gray hair at bay? Many people go to great lengths to cover up their grays, but fans say one buzzy antioxidant may help to stop that discoloration before it event starts ...

Welcome to Culture Clinic, MedPage Today's collaboration with Northwell Health to offer a healthcare professional's take on the latest viral medical topics. Actress and longtime anti-vaccine activist ...

The FDA approved inhaled ensifentrine (Ohtuvayre) as maintenance treatment for chronic obstructive pulmonary disease (COPD) in adults, drugmaker Verona Pharma announced on Wednesday. A first-in-class ...

The last time I spoke about United Therapeutics (UTHR) it was with respect to a Seeking Alpha article entitled "United Therapeutics: Ability To Expand Tyvaso To Large IPF Market". With respect to this ...

United Therapeutics is making headway in unlocking a new lung disease market for its drug Tyvaso (treprostinil) with a pivotal phase 3 win in idiopathic pulmonary fibrosis (IPF). United’s Teton-2 ...

(RTTNews) - United Therapeutics Corp. (UTHR), Tuesday announced that its TETON-2 study evaluating the use of nebulized Tyvaso (treprostinil) Inhalation Solution for the treatment of idiopathic ...

United Therapeutics Corporation (NASDAQ:UTHR) released data on Tuesday from its TETON-2 study evaluating the use of nebulized Tyvaso (treprostinil) Inhalation Solution for idiopathic pulmonary ...